SG11201401183UA - Ecm composition, tumor microenvironment platform and methods thereof - Google Patents

Ecm composition, tumor microenvironment platform and methods thereof

Info

Publication number
SG11201401183UA
SG11201401183UA SG11201401183UA SG11201401183UA SG11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA SG 11201401183U A SG11201401183U A SG 11201401183UA
Authority
SG
Singapore
Prior art keywords
methods
tumor microenvironment
ecm composition
microenvironment platform
platform
Prior art date
Application number
SG11201401183UA
Inventor
Mallikarjun Sundaram
Pradip Majumder
Biswanath Majumder
Misti Jain
Saravanan Thiagarajan
Dency Pinto
Padhma Radhakrishnan
Original Assignee
Mitra Biotech Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitra Biotech Private Ltd filed Critical Mitra Biotech Private Ltd
Publication of SG11201401183UA publication Critical patent/SG11201401183UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201401183UA 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof SG11201401183UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Publications (1)

Publication Number Publication Date
SG11201401183UA true SG11201401183UA (en) 2014-09-26

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401183UA SG11201401183UA (en) 2011-10-04 2012-10-04 Ecm composition, tumor microenvironment platform and methods thereof

Country Status (14)

Country Link
US (7) US20140228246A1 (en)
EP (1) EP2764099B1 (en)
JP (2) JP6147259B2 (en)
AU (1) AU2012320088C1 (en)
CA (1) CA2850274A1 (en)
CY (1) CY1120087T1 (en)
DK (1) DK2764099T3 (en)
ES (1) ES2660975T3 (en)
HU (1) HUE036537T2 (en)
NO (1) NO2764099T3 (en)
PT (1) PT2764099T (en)
SG (1) SG11201401183UA (en)
TR (1) TR201802420T4 (en)
WO (1) WO2013050962A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593438B (en) 2013-05-31 2019-07-05 伊顿智能动力有限公司 For reducing the hydraulic system and method for swing arm bounce by balanced protection
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
CN103966168B (en) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 Tumor living tissue in-vitro culture system and culture method
WO2016154082A2 (en) * 2015-03-23 2016-09-29 Tang Yao Methods of primary tissue culture and drug screening using autologous serum and fluids
JP6135795B2 (en) * 2015-04-22 2017-05-31 小野薬品工業株式会社 Lead compound extraction method, drug discovery target selection method, scatter diagram generation device, data visualization method and visualization device
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
EP3365436B1 (en) * 2015-10-20 2021-09-08 Celcuity Inc. Methods of preparing a primary cell sample
CN106047788A (en) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 Culture medium for high-density cell culture system
GB2555787A (en) 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
JP2020510444A (en) * 2017-02-08 2020-04-09 ミトラ アールエックスディーエックス, インコーポレイテッドMitra Rxdx, Inc. How to predict clinical outcomes of anticancer drugs
JP2020516243A (en) 2017-04-05 2020-06-11 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． Ex vivo culture system and method of using the same
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (en) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Methods of predicting response to temporally sequenced combination therapy
GB201818885D0 (en) 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172591A1 (en) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. A method to predict a patient's response to an anti-cancer drug from an expression level of a set of genes
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
CN112961830A (en) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 Oral squamous carcinoma tissue acellular matrix and preparation method and application thereof
IL309061A (en) 2021-06-06 2024-02-01 Yeda res & development co ltd Combined treatment for cancer
CN113774025B (en) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 Construction method of colorectal cancer cisplatin resistant strain
WO2023067582A1 (en) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Tumor microenvironment platform comprising oral carcinoma for predicting drug sensitivity, drug resistance and disease progression

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (en) * 2002-07-26 2004-10-01 Roussy Inst Gustave PROCESS FOR THE PREPARATION OF AN EXTRACELLULAR MATRIX AND ITS USE FOR THE CULTURE OF TUMOR CELLS
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
WO2010120329A1 (en) * 2009-04-15 2010-10-21 The University Of Medicine And Dentistry Of New Jersey Reconstituted tumor microenvironment for anticancer drug development
WO2011148669A1 (en) * 2010-05-25 2011-12-01 株式会社 島津製作所 Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample

Also Published As

Publication number Publication date
TR201802420T4 (en) 2018-03-21
JP2017061448A (en) 2017-03-30
DK2764099T3 (en) 2018-02-26
CA2850274A1 (en) 2013-04-11
NO2764099T3 (en) 2018-04-21
AU2012320088C1 (en) 2016-03-17
EP2764099A1 (en) 2014-08-13
US20190353640A1 (en) 2019-11-21
HUE036537T2 (en) 2018-07-30
PT2764099T (en) 2018-02-28
ES2660975T3 (en) 2018-03-26
US20190383796A1 (en) 2019-12-19
US20140228246A1 (en) 2014-08-14
US20200064333A1 (en) 2020-02-27
AU2012320088B2 (en) 2015-07-02
AU2012320088A1 (en) 2014-05-01
JP6378273B2 (en) 2018-08-22
CY1120087T1 (en) 2018-12-12
WO2013050962A1 (en) 2013-04-11
US20190383795A1 (en) 2019-12-19
EP2764099B1 (en) 2017-11-22
US20190170730A1 (en) 2019-06-06
US20190346428A1 (en) 2019-11-14
AU2012320088B9 (en) 2015-07-16
JP6147259B2 (en) 2017-06-14
EP2764099A4 (en) 2015-05-06
JP2014534809A (en) 2014-12-25

Similar Documents

Publication Publication Date Title
SG11201401183UA (en) Ecm composition, tumor microenvironment platform and methods thereof
IL269804A (en) Protein-active agent conjugates and method for preparing the same
IL253870A0 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
HK1243344A1 (en) Antibody formulations and methods
IL222465A0 (en) Certain amino-pyridazines, compositions thereof, and methods for their use
EP2560488A4 (en) Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
IL225597A0 (en) Pharmaceutical composition, methods for treating and uses thereof
HK1167942A1 (en) Self-testing transceiver and self-testing method thereof
GB201106433D0 (en) Composition and method
EP2729145A4 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
IL223436A (en) Methods for preparing tetranor-pgdm and tetranor-pgjm
GB201111496D0 (en) Composition and method
GB201102040D0 (en) Composition and method